Jun Li, Huiran Yue, Wenzhi Li, Guohua Zhu, Tingting Zhu, Ruifang Chen, & Xin Lu. (2021). Bevacizumab confers significant improvements in survival for ovarian cancer patients with low miR-25 expression and high miR-142 expression. BMC.
Chicago Style (17th ed.) CitationJun Li, Huiran Yue, Wenzhi Li, Guohua Zhu, Tingting Zhu, Ruifang Chen, and Xin Lu. Bevacizumab Confers Significant Improvements in Survival for Ovarian Cancer Patients with Low MiR-25 Expression and High MiR-142 Expression. BMC, 2021.
MLA (9th ed.) CitationJun Li, et al. Bevacizumab Confers Significant Improvements in Survival for Ovarian Cancer Patients with Low MiR-25 Expression and High MiR-142 Expression. BMC, 2021.
Warning: These citations may not always be 100% accurate.